Our overall results suggest that these drugs often have a relatively weak effect on proangiogenic CXCL8 that is released at high levels by AML cells for most patients; a strong inhibitory effect on this proangiogenic mediator was only seen for a subset of patients and an increased release was often seen for the stromal cells. Here, CXCL8 is linked to acute myeloid leukemia.